BACKGROUND: Since the initial reports of human epidermal growth factor receptor 2 (HER-2) expression as being prognostic in osteosarcoma, numerous small studies varying in the interpretation of the immunohistochemical (IHC) staining patterns have produced conflicting results. The Children's Oncology Group therefore embarked on a prospective biology study in a larger sample of patients to define in osteosarcoma the prognostic value of HER-2 expression using the methodology employed in the initial North American study describing an association between HER-2 expression and outcome. PROCEDURE: The analytic patient population was comprised of 149 patients with newly diagnosed osteosarcoma, 135 with localized disease and 14 with metastatic disease, all of whom had follow up clinical data. Paraffin embedded material from the diagnostic biopsy was stained with CB11 antibody and scored by two independent observers. Correlation of HER-2 IHC score and demographic variables was analyzed using a Fisher's exact test and correlation with survival using a Kaplan-Meier analysis. RESULTS: No association was found with HER-2 status and any of the demographic variables tested including the presence or absence of metastatic disease at diagnosis. No association was found between HER-2 status and either event free survival or overall survival in the patients with localized disease. CONCLUSION: HER-2 expression is not prognostic in osteosarcoma in the context of this large prospective study. HER-2 expression cannot be used as a basis for stratification of therapy. Identification of potential prognostic factors should occur in the context of large multi-institutional biology studies.
BACKGROUND: Since the initial reports of human epidermal growth factor receptor 2 (HER-2) expression as being prognostic in osteosarcoma, numerous small studies varying in the interpretation of the immunohistochemical (IHC) staining patterns have produced conflicting results. The Children's Oncology Group therefore embarked on a prospective biology study in a larger sample of patients to define in osteosarcoma the prognostic value of HER-2 expression using the methodology employed in the initial North American study describing an association between HER-2 expression and outcome. PROCEDURE: The analytic patient population was comprised of 149 patients with newly diagnosed osteosarcoma, 135 with localized disease and 14 with metastatic disease, all of whom had follow up clinical data. Paraffin embedded material from the diagnostic biopsy was stained with CB11 antibody and scored by two independent observers. Correlation of HER-2 IHC score and demographic variables was analyzed using a Fisher's exact test and correlation with survival using a Kaplan-Meier analysis. RESULTS: No association was found with HER-2 status and any of the demographic variables tested including the presence or absence of metastatic disease at diagnosis. No association was found between HER-2 status and either event free survival or overall survival in the patients with localized disease. CONCLUSION:HER-2 expression is not prognostic in osteosarcoma in the context of this large prospective study. HER-2 expression cannot be used as a basis for stratification of therapy. Identification of potential prognostic factors should occur in the context of large multi-institutional biology studies.
Authors: S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda Journal: J Natl Cancer Inst Date: 2000-12-06 Impact factor: 13.506
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Holly Zhou; R Lor Randall; Arthur R Brothman; Teresa Maxwell; Cheryl M Coffin; Robert E Goldsby Journal: J Pediatr Hematol Oncol Date: 2003-01 Impact factor: 1.289
Authors: Cindy L Schwartz; Richard Gorlick; Lisa Teot; Mark Krailo; Zhengjia Chen; Allen Goorin; Holcombe E Grier; Mark L Bernstein; Paul Meyers Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: M Onda; S Matsuda; S Higaki; T Iijima; J Fukushima; A Yokokura; T Kojima; H Horiuchi; T Kurokawa; T Yamamoto Journal: Cancer Date: 1996-01-01 Impact factor: 6.860
Authors: Jason Glover; Tsz-Kwong Man; Donald A Barkauskas; David Hall; Tanya Tello; Mary Beth Sullivan; Richard Gorlick; Katherine Janeway; Holcombe Grier; Ching Lau; Jeffrey A Toretsky; Scott C Borinstein; Chand Khanna; Timothy M Fan Journal: PLoS One Date: 2017-07-21 Impact factor: 3.240